Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

Similar articles for PubMed (Select 23658373)

1.

Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.

Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD.

Ann Oncol. 2013 Aug;24(8):2092-7. doi: 10.1093/annonc/mdt155. Epub 2013 May 8.

2.

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.

Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.

PLoS One. 2013 Jun 13;8(6):e65166. doi: 10.1371/journal.pone.0065166. Print 2013.

3.

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.

Xu J, Tian D.

Curr Med Res Opin. 2014 Jan;30(1):67-74. doi: 10.1185/03007995.2013.844116. Epub 2013 Oct 4. Review.

PMID:
24028709
4.

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.

Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, Richards CJ, Choueiri TK.

Br J Cancer. 2013 Jun 25;108(12):2478-84. doi: 10.1038/bjc.2013.278. Epub 2013 Jun 4. Review.

5.

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.

Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.

Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15.

PMID:
24787966
6.

mTOR inhibitors in advanced renal cell carcinoma.

Voss MH, Molina AM, Motzer RJ.

Hematol Oncol Clin North Am. 2011 Aug;25(4):835-52. doi: 10.1016/j.hoc.2011.04.008. Review.

7.

Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.

Peng L, Zhou Y, Ye X, Zhao Q.

Tumour Biol. 2015 Feb;36(2):643-54. doi: 10.1007/s13277-014-2669-3. Epub 2014 Oct 4.

PMID:
25281033
8.

Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.

Shameem R, Lacouture M, Wu S.

Cancer Invest. 2015 Mar;33(3):70-7. doi: 10.3109/07357907.2014.1001893. Epub 2015 Jan 30.

PMID:
25635371
9.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578. Epub 2014 Jan 23.

10.

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.

Weikert S, Kempkensteffen C, Busch J, Johannsen M, Grünwald V, Zimmermann K, Flörcken A, Westermann J, Weinkauf L, Miller K, Keilholz U.

World J Urol. 2013 Aug;31(4):805-9. doi: 10.1007/s00345-011-0676-1. Epub 2011 Apr 22.

PMID:
21512806
11.

Everolimus in renal cell carcinoma.

Wang Y.

Drugs Today (Barc). 2010 Aug;46(8):557-66. doi: 10.1358/dot.2010.46.8.1516824. Review.

PMID:
20830316
12.

Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.

Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Hutson TE.

Clin Genitourin Cancer. 2013 Jun;11(2):115-20. doi: 10.1016/j.clgc.2012.09.008. Epub 2012 Oct 12.

PMID:
23063578
13.

Everolimus for the treatment of advanced renal cell carcinoma.

Amato R.

Expert Opin Pharmacother. 2011 May;12(7):1143-55. doi: 10.1517/14656566.2011.571382. Epub 2011 Apr 7. Review.

PMID:
21470068
14.

Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, Cincotta M, Shapiro M, Duran I, Berkenblit A.

J Clin Oncol. 2011 May 1;29(13):1750-6. doi: 10.1200/JCO.2010.29.2235. Epub 2011 Mar 28.

15.
16.

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.

Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.

Oncologist. 2014 Apr;19(4):354-5. doi: 10.1634/theoncologist.2014-0020. Epub 2014 Mar 27.

17.

Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.

Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, Bracarda S, Hutson TE, Escudier B, Grünwald V, Kim D, Panneerselvam A, Anak O, Motzer RJ.

Eur Urol. 2012 Apr;61(4):826-33. doi: 10.1016/j.eururo.2011.12.057. Epub 2012 Jan 5.

18.

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.

Danesi R, Boni JP, Ravaud A.

Cancer Treat Rev. 2013 Nov;39(7):784-92. doi: 10.1016/j.ctrv.2012.12.012. Epub 2013 Jan 30. Review.

PMID:
23375248
19.

Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

Figlin RA.

Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Review.

PMID:
18607393
20.

Temsirolimus: a safety and efficacy review.

Bukowski RM.

Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Review.

PMID:
22861825
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk